Oxehealth closes latest round of funding with £2m of investment
Oxehealth, the vital signs software developer spun out from the University of Oxford’s Institute of Biomedical Engineering, today announces the results of its latest round of funding, which has seen investment from IP Group plc, one of its managed funds, IP Venture Fund II LP, and ORA.
The company’s patented Oxecam clinical technology, developed by world-leading scientist Professor Lionel Tarassenko, enables a digital video camera, tablet or phone to monitor the vital signs of an individual, without the need for physical contact or expensive proprietary equipment.
The technology has a number of exciting applications in both healthcare and wider consumer markets and has the potential to not only make patients safer but also save valuable nursing time otherwise spent manually collecting and recording vital signs. The funds will be used to support the development of specific applications and prototypes as well as the extension of the core technology.
Richard Griffiths, Executive Chairman of ORA, is one of the UK’s leading investors in technology. Richard who was an early investor in IP Group plc, has also invested in other IP Group portfolio companies including Oxford Nanopore Technologies Ltd and Tissue Regenix Group plc. As well as a raft of other high tech and small cap companies including Nanoco Group plc, Oxford Pharmascience Group plc, Silence Therapeutics plc, Plant Health Care plc and GVC Holdings plc.
Richard said: “I’m delighted to be backing Oxehealth which has an incredibly exciting technology and a management team with a proven track record of delivery.”
Existing investors IP Group plc, IP Venture Fund II LP, Chairman Allan Wood and CEO Jonathan Chevallier also invested further in the current round.
As well as influential external backers, Oxehealth is supported within by a strong board and advisors which include Warren East, ex-ARM CEO.
Notes to Editor:
Oxehealth Ltd is a biomedical software developer spun out from the University of Oxford’s Institute of Biomedical Engineering in 2012. Oxehealth is focused on providing advanced solutions which monitor vital signs. It does this through a range of software products with embedded intelligent algorithms which combine three key attributes: complex signal processing to allow accurate non-contact monitoring; machine learning, to provide personalised healthcare models; and clinical validation.
These solutions have the capability to transform the next generation of healthcare and patient monitoring. Its patented Oxecam clinical technology developed in the research labs of world-leading scientist Professor Lionel Tarassenko and backed by IP Group plc., enables a digital camera to monitor the vital signs (heart rate, respiratory rate and oxygen saturation) of individuals, without the need for expensive proprietary equipment. The vital sign measurements have been clinically validated in studies at the Oxford Kidney Unit.
Applications for the clinical technology include post-operative monitoring, COPD, assisted living, and providing lower cost smartphone or webcam diagnostics in inaccessible situations such as underdeveloped third world countries.
There are also opportunities in other sectors such as automotive, where the continuous monitoring of vital signs could be life-saving.
For further information, contact Louise Fielding-Smith, at firstname.lastname@example.org or on 01962 677 002, 07877 340671.
Support InfoStride News' Credible Journalism: Only credible journalism can guarantee a fair, accountable and transparent society, including democracy and government. It involves a lot of efforts and money. We need your support. Click here to Donate